Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Completed 5Active not recruiting 3Recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Colorectal Neoplasms 26Pancreatic Neoplasms 12Stomach Neoplasms 11Colonic Neoplasms 9Rectal Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Esophageal Neoplasms 7Adenocarcinoma Of Esophagus 7Burkitt Lymphoma 6Neoplasms 5Cholangiocarcinoma 5Neoplasm Metastasis 4Carcinoma, Non-Small-Cell Lung 4Urinary Bladder Neoplasms 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Ovarian Neoplasms 3Gastrointestinal Neoplasms 3Esophageal Squamous Cell Carcinoma 3Squamous Cell Carcinoma of Head and Neck 2Lung Neoplasms 2Leukemia, Biphenotypic, Acute 2Leukemia 2Gallbladder Neoplasms 2Carcinoma, Renal Cell 2Adenocarcinoma 2Uterine Cervical Neoplasms 1Urethral Neoplasms 1Urachal cancer 1Unresectable Colorectal Cancer 1

Interventions

pembrolizumab 35Cisplatin 12Paclitaxel 9lenvatinib 7Carboplatin 6belzutifan 5Saline Solution 4Pemetrexed 4Oxaliplatin 4Fluorouracil 4Leucovorin 3Etoposide 3Docetaxel 3Albumin-Bound Paclitaxel 3130-nm albumin-bound paclitaxel 3olaparib 2enfortumab vedotin 2durvalumab 2Surgical Procedures, Operative 2Radiotherapy 2Levoleucovorin 2Glucose 2Capecitabine 2Bevacizumab 2zanidatamab 1tislelizumab 1sacituzumab govitecan 1liposomal doxorubicin 1enzalutamide 1balstilimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Parkinson Disease 4, Autosomal Dominant Lewy Body × Leucovorin × Clear all
NCT05239741 2026-05-22

MK-3475-C66

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
100 enrolled
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT04210115 2026-05-13

KEYNOTE 975

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
703 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma

NCT04949256 2025-12-15

MK-7902-014

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
864 enrolled
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡